Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06907173 · ClinicalTrials.gov registry record · Phase 3

Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)

A Phase 3 study of Status Epilepticus, sponsored by University of Virginia.

Recruiting
Registry status
Phase 3
Development phase
770
Enrollment target
20
Study locations

NCT06907173 is a Phase 3 study of Status Epilepticus that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 770 participants, below the 2,756-participant average among 10 other Status Epilepticus trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06907173, a Phase 3 study of Status Epilepticus, is actively recruiting participants, sponsored by University of Virginia.

RECRUITING
Registry status
Phase 3
Development phase
770 participants
Enrollment target
20
Study locations

Study Summary

The goal of this clinical trial is to determine if treatment of patients with two doses of ketamine plus levetiracetam versus levetiracetam alone leads to more effective control of status epilepticus.

Conditions Studied

Status Epilepticus

Interventions

  • DRUG Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET)
  • DRUG Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET)
  • DRUG Levetiracetam (LEV) (60 mg/Kg)

Study Locations (20)

California

  • Ronald Reagan UCLA Medical Center - Los Angeles
  • Children's Hospital Los Angeles - Los Angeles
  • UC Davis Medical Center - Sacramento

Illinois

  • Northwestern Memorial Hospital - Chicago
  • Comer Children's Hospital - Chicago
  • University of Chicago Medical Center - Chicago

Delaware

  • Christiana Hospital - Newark
  • Nemours Children's Hospital - Wilmington

North Carolina

  • Duke Regional Hospital - Durham
  • Duke University Hospital - Durham

Alabama

  • Arthur M. Blank Hospital - Georgia

Arizona

  • Banner University Medical Center - Tucson Campus - Tucson

Connecticut

  • Yale New Haven Hospital - New Haven

District of Columbia

  • Children's National Medical Center - Washington D.C.

Trial Details

FieldValue
Enrollment Target 770 participants
Start Date 2026-02
Est. Completion 2029-12
Phase Phase 3

Sponsor

University of Virginia

449 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06907173

The ClinicalTrials.gov registry entry for NCT06907173 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 770 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,756-participant average among 10 other Status Epilepticus trials with a reported enrollment target (72% lower). The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Status Epilepticus appearing as the primary indexed condition, and to 3 interventions - of which Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET) is the first listed.

NCT06907173 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Illinois, Delaware.

Frequently Asked Questions

What is clinical trial NCT06907173 about?

NCT06907173 is a clinical study titled "Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)". The goal of this clinical trial is to determine if treatment of patients with two doses of ketamine plus levetiracetam versus levetiracetam alone leads to more effective control of status epilepticus.

What is the current status of trial NCT06907173?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 770 participants. The study started on 2026-02. Estimated completion is 2029-12.

What conditions does trial NCT06907173 study?

This clinical trial studies the following conditions: Status Epilepticus.

What interventions are being tested in trial NCT06907173?

The interventions under investigation include: Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET) (DRUG), Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET) (DRUG), Levetiracetam (LEV) (60 mg/Kg) (DRUG).

Who is sponsoring clinical trial NCT06907173?

This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06907173 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Status Epilepticus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Status Epilepticus

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.